nodes	percent_of_prediction	percent_of_DWPC	metapath
Methsuximide—CACNA1I—NCAM signaling for neurite out-growth—SPTBN4—kidney cancer	0.0143	0.057	CbGpPWpGaD
Methsuximide—CACNA1G—NCAM signaling for neurite out-growth—SPTBN4—kidney cancer	0.0106	0.0421	CbGpPWpGaD
Methsuximide—CACNA1H—NCAM signaling for neurite out-growth—SPTBN4—kidney cancer	0.0102	0.0407	CbGpPWpGaD
Methsuximide—CACNA1H—Corticotropin-releasing hormone—FOSL2—kidney cancer	0.00878	0.035	CbGpPWpGaD
Methsuximide—CACNA1H—Corticotropin-releasing hormone—FOSL1—kidney cancer	0.00586	0.0233	CbGpPWpGaD
Methsuximide—CACNA1I—Axon guidance—UNC5C—kidney cancer	0.00542	0.0216	CbGpPWpGaD
Methsuximide—CACNA1G—Regulation of nuclear beta catenin signaling and target gene transcription—MITF—kidney cancer	0.00495	0.0197	CbGpPWpGaD
Methsuximide—CACNA1H—Corticotropin-releasing hormone—JUND—kidney cancer	0.00453	0.018	CbGpPWpGaD
Methsuximide—Proteinuria—Capecitabine—kidney cancer	0.00432	0.00585	CcSEcCtD
Methsuximide—Vision blurred—Pazopanib—kidney cancer	0.0043	0.00582	CcSEcCtD
Methsuximide—Protein urine present—Capecitabine—kidney cancer	0.00426	0.00577	CcSEcCtD
Methsuximide—CACNA1I—Axon guidance—SPTBN4—kidney cancer	0.00411	0.0164	CbGpPWpGaD
Methsuximide—CACNA1I—Axon guidance—L1CAM—kidney cancer	0.00411	0.0164	CbGpPWpGaD
Methsuximide—Pancytopenia—Sunitinib—kidney cancer	0.0041	0.00555	CcSEcCtD
Methsuximide—Leukopenia—Pazopanib—kidney cancer	0.00409	0.00553	CcSEcCtD
Methsuximide—Weight decreased—Sorafenib—kidney cancer	0.00406	0.0055	CcSEcCtD
Methsuximide—CACNA1G—Axon guidance—UNC5C—kidney cancer	0.004	0.0159	CbGpPWpGaD
Methsuximide—Ataxia—Vincristine—kidney cancer	0.00398	0.00538	CcSEcCtD
Methsuximide—Stevens-Johnson syndrome—Sorafenib—kidney cancer	0.00397	0.00537	CcSEcCtD
Methsuximide—Weight decreased—Sunitinib—kidney cancer	0.00391	0.00529	CcSEcCtD
Methsuximide—Pancytopenia—Dactinomycin—kidney cancer	0.00389	0.00526	CcSEcCtD
Methsuximide—CACNA1H—Axon guidance—UNC5C—kidney cancer	0.00387	0.0154	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—UNC5C—kidney cancer	0.00387	0.0154	CbGpPWpGaD
Methsuximide—Stevens-Johnson syndrome—Sunitinib—kidney cancer	0.00382	0.00517	CcSEcCtD
Methsuximide—Hiccups—Capecitabine—kidney cancer	0.0038	0.00514	CcSEcCtD
Methsuximide—Erythema multiforme—Erlotinib—kidney cancer	0.00378	0.00511	CcSEcCtD
Methsuximide—Anorexia—Temsirolimus—kidney cancer	0.00377	0.0051	CcSEcCtD
Methsuximide—Stevens-Johnson syndrome—Dactinomycin—kidney cancer	0.00362	0.00489	CcSEcCtD
Methsuximide—Insomnia—Temsirolimus—kidney cancer	0.00358	0.00484	CcSEcCtD
Methsuximide—Anorexia—Pazopanib—kidney cancer	0.00355	0.00481	CcSEcCtD
Methsuximide—Somnolence—Temsirolimus—kidney cancer	0.00352	0.00476	CcSEcCtD
Methsuximide—Pancytopenia—Vincristine—kidney cancer	0.00347	0.0047	CcSEcCtD
Methsuximide—Decreased appetite—Temsirolimus—kidney cancer	0.00344	0.00465	CcSEcCtD
Methsuximide—Gastrointestinal disorder—Temsirolimus—kidney cancer	0.00342	0.00462	CcSEcCtD
Methsuximide—Erythema multiforme—Sorafenib—kidney cancer	0.0034	0.0046	CcSEcCtD
Methsuximide—Vision blurred—Everolimus—kidney cancer	0.0034	0.0046	CcSEcCtD
Methsuximide—Constipation—Temsirolimus—kidney cancer	0.00338	0.00458	CcSEcCtD
Methsuximide—Insomnia—Pazopanib—kidney cancer	0.00337	0.00456	CcSEcCtD
Methsuximide—Somnolence—Pazopanib—kidney cancer	0.00331	0.00448	CcSEcCtD
Methsuximide—Weight decreased—Vincristine—kidney cancer	0.00331	0.00447	CcSEcCtD
Methsuximide—CYP2C19—Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET)—CYP1A1—kidney cancer	0.00329	0.0131	CbGpPWpGaD
Methsuximide—Pancytopenia—Gemcitabine—kidney cancer	0.00329	0.00446	CcSEcCtD
Methsuximide—Erythema multiforme—Sunitinib—kidney cancer	0.00327	0.00443	CcSEcCtD
Methsuximide—Leukopenia—Vinblastine—kidney cancer	0.00324	0.00438	CcSEcCtD
Methsuximide—Decreased appetite—Pazopanib—kidney cancer	0.00324	0.00438	CcSEcCtD
Methsuximide—Gastrointestinal pain—Temsirolimus—kidney cancer	0.00324	0.00438	CcSEcCtD
Methsuximide—Leukopenia—Everolimus—kidney cancer	0.00323	0.00437	CcSEcCtD
Methsuximide—Gastrointestinal disorder—Pazopanib—kidney cancer	0.00322	0.00435	CcSEcCtD
Methsuximide—Ataxia—Paclitaxel—kidney cancer	0.00316	0.00427	CcSEcCtD
Methsuximide—Abdominal pain—Temsirolimus—kidney cancer	0.00313	0.00423	CcSEcCtD
Methsuximide—Erythema multiforme—Dactinomycin—kidney cancer	0.0031	0.00419	CcSEcCtD
Methsuximide—CACNA1H—Corticotropin-releasing hormone—JUNB—kidney cancer	0.00308	0.0123	CbGpPWpGaD
Methsuximide—Stevens-Johnson syndrome—Gemcitabine—kidney cancer	0.00307	0.00415	CcSEcCtD
Methsuximide—Gastrointestinal pain—Pazopanib—kidney cancer	0.00305	0.00412	CcSEcCtD
Methsuximide—Antipyrine—PTGS1—kidney cancer	0.00303	0.316	CrCbGaD
Methsuximide—CACNA1G—Axon guidance—L1CAM—kidney cancer	0.00303	0.0121	CbGpPWpGaD
Methsuximide—CACNA1G—Axon guidance—SPTBN4—kidney cancer	0.00303	0.0121	CbGpPWpGaD
Methsuximide—CYP2C19—Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE)—CYP1A1—kidney cancer	0.003	0.0119	CbGpPWpGaD
Methsuximide—Haematuria—Gemcitabine—kidney cancer	0.00295	0.00399	CcSEcCtD
Methsuximide—Abdominal pain—Pazopanib—kidney cancer	0.00295	0.00399	CcSEcCtD
Methsuximide—CACNA1H—Axon guidance—L1CAM—kidney cancer	0.00293	0.0117	CbGpPWpGaD
Methsuximide—CACNA1H—Axon guidance—SPTBN4—kidney cancer	0.00293	0.0117	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—L1CAM—kidney cancer	0.00293	0.0117	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—SPTBN4—kidney cancer	0.00293	0.0117	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—UNC5C—kidney cancer	0.00285	0.0114	CbGpPWpGaD
Methsuximide—Anorexia—Vinblastine—kidney cancer	0.00282	0.00381	CcSEcCtD
Methsuximide—Anorexia—Everolimus—kidney cancer	0.00281	0.00379	CcSEcCtD
Methsuximide—Leukopenia—Sorafenib—kidney cancer	0.0028	0.00379	CcSEcCtD
Methsuximide—CACNA1H—Developmental Biology—UNC5C—kidney cancer	0.00276	0.011	CbGpPWpGaD
Methsuximide—Pancytopenia—Paclitaxel—kidney cancer	0.00276	0.00373	CcSEcCtD
Methsuximide—Diarrhoea—Temsirolimus—kidney cancer	0.00271	0.00366	CcSEcCtD
Methsuximide—Anorexia—Erlotinib—kidney cancer	0.00271	0.00366	CcSEcCtD
Methsuximide—Leukopenia—Sunitinib—kidney cancer	0.0027	0.00365	CcSEcCtD
Methsuximide—Insomnia—Everolimus—kidney cancer	0.00266	0.0036	CcSEcCtD
Methsuximide—Irritability—Capecitabine—kidney cancer	0.00263	0.00356	CcSEcCtD
Methsuximide—Weight decreased—Paclitaxel—kidney cancer	0.00263	0.00355	CcSEcCtD
Methsuximide—Erythema multiforme—Gemcitabine—kidney cancer	0.00262	0.00355	CcSEcCtD
Methsuximide—Somnolence—Everolimus—kidney cancer	0.00262	0.00354	CcSEcCtD
Methsuximide—Dizziness—Temsirolimus—kidney cancer	0.00262	0.00354	CcSEcCtD
Methsuximide—Ataxia—Capecitabine—kidney cancer	0.00259	0.00351	CcSEcCtD
Methsuximide—Insomnia—Erlotinib—kidney cancer	0.00257	0.00347	CcSEcCtD
Methsuximide—Decreased appetite—Vinblastine—kidney cancer	0.00257	0.00347	CcSEcCtD
Methsuximide—Stevens-Johnson syndrome—Paclitaxel—kidney cancer	0.00257	0.00347	CcSEcCtD
Methsuximide—CACNA1I—Developmental Biology—CER1—kidney cancer	0.00256	0.0102	CbGpPWpGaD
Methsuximide—Decreased appetite—Everolimus—kidney cancer	0.00256	0.00346	CcSEcCtD
Methsuximide—Leukopenia—Dactinomycin—kidney cancer	0.00255	0.00345	CcSEcCtD
Methsuximide—Diarrhoea—Pazopanib—kidney cancer	0.00255	0.00345	CcSEcCtD
Methsuximide—Gastrointestinal disorder—Everolimus—kidney cancer	0.00254	0.00344	CcSEcCtD
Methsuximide—Constipation—Vinblastine—kidney cancer	0.00253	0.00342	CcSEcCtD
Methsuximide—Constipation—Everolimus—kidney cancer	0.00252	0.0034	CcSEcCtD
Methsuximide—Vomiting—Temsirolimus—kidney cancer	0.00252	0.0034	CcSEcCtD
Methsuximide—Rash—Temsirolimus—kidney cancer	0.00249	0.00337	CcSEcCtD
Methsuximide—Dermatitis—Temsirolimus—kidney cancer	0.00249	0.00337	CcSEcCtD
Methsuximide—Headache—Temsirolimus—kidney cancer	0.00248	0.00335	CcSEcCtD
Methsuximide—CACNA1I—NCAM signaling for neurite out-growth—RAF1—kidney cancer	0.00247	0.00984	CbGpPWpGaD
Methsuximide—Haematuria—Paclitaxel—kidney cancer	0.00247	0.00334	CcSEcCtD
Methsuximide—Decreased appetite—Erlotinib—kidney cancer	0.00247	0.00334	CcSEcCtD
Methsuximide—Dizziness—Pazopanib—kidney cancer	0.00246	0.00333	CcSEcCtD
Methsuximide—Gastrointestinal disorder—Erlotinib—kidney cancer	0.00245	0.00332	CcSEcCtD
Methsuximide—Hiccups—Doxorubicin—kidney cancer	0.00245	0.00331	CcSEcCtD
Methsuximide—Anorexia—Sorafenib—kidney cancer	0.00243	0.00329	CcSEcCtD
Methsuximide—Feeling abnormal—Vinblastine—kidney cancer	0.00243	0.00329	CcSEcCtD
Methsuximide—Constipation—Erlotinib—kidney cancer	0.00243	0.00328	CcSEcCtD
Methsuximide—Feeling abnormal—Everolimus—kidney cancer	0.00243	0.00328	CcSEcCtD
Methsuximide—Gastrointestinal pain—Vinblastine—kidney cancer	0.00242	0.00327	CcSEcCtD
Methsuximide—Gastrointestinal pain—Everolimus—kidney cancer	0.00241	0.00326	CcSEcCtD
Methsuximide—Vomiting—Pazopanib—kidney cancer	0.00237	0.00321	CcSEcCtD
Methsuximide—Rash—Pazopanib—kidney cancer	0.00235	0.00318	CcSEcCtD
Methsuximide—Nausea—Temsirolimus—kidney cancer	0.00235	0.00318	CcSEcCtD
Methsuximide—Dermatitis—Pazopanib—kidney cancer	0.00235	0.00318	CcSEcCtD
Methsuximide—Anorexia—Sunitinib—kidney cancer	0.00234	0.00317	CcSEcCtD
Methsuximide—Abdominal pain—Vinblastine—kidney cancer	0.00234	0.00316	CcSEcCtD
Methsuximide—Headache—Pazopanib—kidney cancer	0.00233	0.00316	CcSEcCtD
Methsuximide—Abdominal pain—Everolimus—kidney cancer	0.00233	0.00315	CcSEcCtD
Methsuximide—Gastrointestinal pain—Erlotinib—kidney cancer	0.00232	0.00314	CcSEcCtD
Methsuximide—CACNA1I—Developmental Biology—HNF1A—kidney cancer	0.00232	0.00923	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—EPAS1—kidney cancer	0.00232	0.00923	CbGpPWpGaD
Methsuximide—Leukopenia—Vincristine—kidney cancer	0.00228	0.00308	CcSEcCtD
Methsuximide—Pancytopenia—Capecitabine—kidney cancer	0.00226	0.00306	CcSEcCtD
Methsuximide—Abdominal pain—Erlotinib—kidney cancer	0.00224	0.00304	CcSEcCtD
Methsuximide—Insomnia—Sunitinib—kidney cancer	0.00222	0.00301	CcSEcCtD
Methsuximide—Decreased appetite—Sorafenib—kidney cancer	0.00222	0.003	CcSEcCtD
Methsuximide—Anorexia—Dactinomycin—kidney cancer	0.00222	0.003	CcSEcCtD
Methsuximide—Nausea—Pazopanib—kidney cancer	0.00221	0.00299	CcSEcCtD
Methsuximide—Gastrointestinal disorder—Sorafenib—kidney cancer	0.00221	0.00298	CcSEcCtD
Methsuximide—Erythema multiforme—Paclitaxel—kidney cancer	0.0022	0.00297	CcSEcCtD
Methsuximide—Constipation—Sorafenib—kidney cancer	0.00218	0.00296	CcSEcCtD
Methsuximide—Leukopenia—Gemcitabine—kidney cancer	0.00216	0.00293	CcSEcCtD
Methsuximide—CACNA1G—Developmental Biology—SPTBN4—kidney cancer	0.00216	0.00861	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—L1CAM—kidney cancer	0.00216	0.00861	CbGpPWpGaD
Methsuximide—Weight decreased—Capecitabine—kidney cancer	0.00216	0.00292	CcSEcCtD
Methsuximide—Decreased appetite—Sunitinib—kidney cancer	0.00214	0.00289	CcSEcCtD
Methsuximide—Gastrointestinal disorder—Sunitinib—kidney cancer	0.00212	0.00287	CcSEcCtD
Methsuximide—Stevens-Johnson syndrome—Capecitabine—kidney cancer	0.00211	0.00285	CcSEcCtD
Methsuximide—Constipation—Sunitinib—kidney cancer	0.0021	0.00284	CcSEcCtD
Methsuximide—CACNA1H—Developmental Biology—SPTBN4—kidney cancer	0.00209	0.00834	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—L1CAM—kidney cancer	0.00209	0.00834	CbGpPWpGaD
Methsuximide—Gastrointestinal pain—Sorafenib—kidney cancer	0.00209	0.00283	CcSEcCtD
Methsuximide—CACNA1G—Regulation of nuclear beta catenin signaling and target gene transcription—APC—kidney cancer	0.00204	0.00811	CbGpPWpGaD
Methsuximide—Urticaria—Sorafenib—kidney cancer	0.00203	0.00275	CcSEcCtD
Methsuximide—Haematuria—Capecitabine—kidney cancer	0.00203	0.00274	CcSEcCtD
Methsuximide—Decreased appetite—Dactinomycin—kidney cancer	0.00202	0.00274	CcSEcCtD
Methsuximide—Diarrhoea—Vinblastine—kidney cancer	0.00202	0.00273	CcSEcCtD
Methsuximide—Abdominal pain—Sorafenib—kidney cancer	0.00202	0.00273	CcSEcCtD
Methsuximide—Diarrhoea—Everolimus—kidney cancer	0.00201	0.00272	CcSEcCtD
Methsuximide—Gastrointestinal pain—Sunitinib—kidney cancer	0.00201	0.00272	CcSEcCtD
Methsuximide—Tension—Paclitaxel—kidney cancer	0.00199	0.00269	CcSEcCtD
Methsuximide—Anorexia—Vincristine—kidney cancer	0.00198	0.00268	CcSEcCtD
Methsuximide—Nervousness—Paclitaxel—kidney cancer	0.00197	0.00266	CcSEcCtD
Methsuximide—Dizziness—Vinblastine—kidney cancer	0.00195	0.00264	CcSEcCtD
Methsuximide—CYP2C19—Melatonin metabolism and effects—ACHE—kidney cancer	0.00195	0.00775	CbGpPWpGaD
Methsuximide—Dizziness—Everolimus—kidney cancer	0.00195	0.00263	CcSEcCtD
Methsuximide—Abdominal pain—Sunitinib—kidney cancer	0.00194	0.00263	CcSEcCtD
Methsuximide—Diarrhoea—Erlotinib—kidney cancer	0.00194	0.00263	CcSEcCtD
Methsuximide—Feeling abnormal—Dactinomycin—kidney cancer	0.00192	0.00259	CcSEcCtD
Methsuximide—Vision blurred—Paclitaxel—kidney cancer	0.00191	0.00258	CcSEcCtD
Methsuximide—Gastrointestinal pain—Dactinomycin—kidney cancer	0.0019	0.00257	CcSEcCtD
Methsuximide—CACNA1I—Developmental Biology—HNF1B—kidney cancer	0.00189	0.00752	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—CER1—kidney cancer	0.00189	0.00752	CbGpPWpGaD
Methsuximide—Insomnia—Vincristine—kidney cancer	0.00188	0.00254	CcSEcCtD
Methsuximide—Anorexia—Gemcitabine—kidney cancer	0.00188	0.00254	CcSEcCtD
Methsuximide—Vomiting—Vinblastine—kidney cancer	0.00188	0.00254	CcSEcCtD
Methsuximide—Dizziness—Erlotinib—kidney cancer	0.00188	0.00254	CcSEcCtD
Methsuximide—CACNA1G—Regulation of nuclear beta catenin signaling and target gene transcription—CDH1—kidney cancer	0.00188	0.00747	CbGpPWpGaD
Methsuximide—Vomiting—Everolimus—kidney cancer	0.00187	0.00253	CcSEcCtD
Methsuximide—Rash—Everolimus—kidney cancer	0.00186	0.00251	CcSEcCtD
Methsuximide—Dermatitis—Everolimus—kidney cancer	0.00185	0.00251	CcSEcCtD
Methsuximide—Headache—Vinblastine—kidney cancer	0.00185	0.0025	CcSEcCtD
Methsuximide—Headache—Everolimus—kidney cancer	0.00184	0.00249	CcSEcCtD
Methsuximide—Abdominal pain—Dactinomycin—kidney cancer	0.00184	0.00249	CcSEcCtD
Methsuximide—CACNA1H—Developmental Biology—CER1—kidney cancer	0.00183	0.00729	CbGpPWpGaD
Methsuximide—CACNA1G—NCAM signaling for neurite out-growth—RAF1—kidney cancer	0.00182	0.00725	CbGpPWpGaD
Methsuximide—Leukopenia—Paclitaxel—kidney cancer	0.00181	0.00245	CcSEcCtD
Methsuximide—Decreased appetite—Vincristine—kidney cancer	0.00181	0.00244	CcSEcCtD
Methsuximide—Vomiting—Erlotinib—kidney cancer	0.00181	0.00244	CcSEcCtD
Methsuximide—Erythema multiforme—Capecitabine—kidney cancer	0.0018	0.00244	CcSEcCtD
Methsuximide—Gastrointestinal disorder—Vincristine—kidney cancer	0.00179	0.00243	CcSEcCtD
Methsuximide—Rash—Erlotinib—kidney cancer	0.00179	0.00242	CcSEcCtD
Methsuximide—Dermatitis—Erlotinib—kidney cancer	0.00179	0.00242	CcSEcCtD
Methsuximide—Insomnia—Gemcitabine—kidney cancer	0.00178	0.00241	CcSEcCtD
Methsuximide—CACNA1I—NCAM signaling for neurite out-growth—MAPK3—kidney cancer	0.00178	0.00709	CbGpPWpGaD
Methsuximide—Headache—Erlotinib—kidney cancer	0.00178	0.00241	CcSEcCtD
Methsuximide—Constipation—Vincristine—kidney cancer	0.00178	0.00241	CcSEcCtD
Methsuximide—CACNA1H—NCAM signaling for neurite out-growth—RAF1—kidney cancer	0.00176	0.00702	CbGpPWpGaD
Methsuximide—Nausea—Vinblastine—kidney cancer	0.00175	0.00237	CcSEcCtD
Methsuximide—Somnolence—Gemcitabine—kidney cancer	0.00175	0.00237	CcSEcCtD
Methsuximide—Nausea—Everolimus—kidney cancer	0.00175	0.00236	CcSEcCtD
Methsuximide—Diarrhoea—Sorafenib—kidney cancer	0.00175	0.00236	CcSEcCtD
Methsuximide—Antipyrine—PTGS2—kidney cancer	0.00173	0.181	CrCbGaD
Methsuximide—Decreased appetite—Gemcitabine—kidney cancer	0.00171	0.00232	CcSEcCtD
Methsuximide—CACNA1G—Developmental Biology—HNF1A—kidney cancer	0.00171	0.0068	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—EPAS1—kidney cancer	0.00171	0.0068	CbGpPWpGaD
Methsuximide—Gastrointestinal disorder—Gemcitabine—kidney cancer	0.0017	0.0023	CcSEcCtD
Methsuximide—Gastrointestinal pain—Vincristine—kidney cancer	0.0017	0.0023	CcSEcCtD
Methsuximide—CACNA1I—NCAM signaling for neurite out-growth—MAPK1—kidney cancer	0.00169	0.00675	CbGpPWpGaD
Methsuximide—Dizziness—Sorafenib—kidney cancer	0.00169	0.00229	CcSEcCtD
Methsuximide—Constipation—Gemcitabine—kidney cancer	0.00169	0.00228	CcSEcCtD
Methsuximide—Nausea—Erlotinib—kidney cancer	0.00169	0.00228	CcSEcCtD
Methsuximide—Diarrhoea—Sunitinib—kidney cancer	0.00168	0.00228	CcSEcCtD
Methsuximide—CACNA1H—Corticotropin-releasing hormone—POMC—kidney cancer	0.00168	0.00669	CbGpPWpGaD
Methsuximide—Ataxia—Doxorubicin—kidney cancer	0.00167	0.00226	CcSEcCtD
Methsuximide—Confusional state—Paclitaxel—kidney cancer	0.00166	0.00225	CcSEcCtD
Methsuximide—CACNA1H—Corticotropin-releasing hormone—BRAF—kidney cancer	0.00166	0.0066	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—HNF1A—kidney cancer	0.00166	0.00659	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—EPAS1—kidney cancer	0.00166	0.00659	CbGpPWpGaD
Methsuximide—CACNA1G—Regulation of nuclear beta catenin signaling and target gene transcription—CDKN2A—kidney cancer	0.00165	0.00659	CbGpPWpGaD
Methsuximide—Abdominal pain—Vincristine—kidney cancer	0.00164	0.00222	CcSEcCtD
Methsuximide—Dizziness—Sunitinib—kidney cancer	0.00163	0.0022	CcSEcCtD
Methsuximide—Feeling abnormal—Gemcitabine—kidney cancer	0.00163	0.0022	CcSEcCtD
Methsuximide—Vomiting—Sorafenib—kidney cancer	0.00162	0.0022	CcSEcCtD
Methsuximide—Rash—Sorafenib—kidney cancer	0.00161	0.00218	CcSEcCtD
Methsuximide—Dermatitis—Sorafenib—kidney cancer	0.00161	0.00218	CcSEcCtD
Methsuximide—CACNA1I—NCAM signaling for neurite out-growth—KRAS—kidney cancer	0.0016	0.00637	CbGpPWpGaD
Methsuximide—Headache—Sorafenib—kidney cancer	0.0016	0.00216	CcSEcCtD
Methsuximide—Diarrhoea—Dactinomycin—kidney cancer	0.00159	0.00215	CcSEcCtD
Methsuximide—CYP2C19—Xenobiotics—CYP1A1—kidney cancer	0.00158	0.0063	CbGpPWpGaD
Methsuximide—CACNA1I—Axon guidance—PAK1—kidney cancer	0.00157	0.00627	CbGpPWpGaD
Methsuximide—Anorexia—Paclitaxel—kidney cancer	0.00157	0.00213	CcSEcCtD
Methsuximide—Vision blurred—Capecitabine—kidney cancer	0.00156	0.00212	CcSEcCtD
Methsuximide—Vomiting—Sunitinib—kidney cancer	0.00156	0.00211	CcSEcCtD
Methsuximide—Rash—Sunitinib—kidney cancer	0.00155	0.0021	CcSEcCtD
Methsuximide—Dermatitis—Sunitinib—kidney cancer	0.00155	0.00209	CcSEcCtD
Methsuximide—Headache—Sunitinib—kidney cancer	0.00154	0.00208	CcSEcCtD
Methsuximide—CYP2C19—Tamoxifen metabolism—CYP1A1—kidney cancer	0.00152	0.00606	CbGpPWpGaD
Methsuximide—Eosinophilia—Doxorubicin—kidney cancer	0.00152	0.00206	CcSEcCtD
Methsuximide—Nausea—Sorafenib—kidney cancer	0.00152	0.00205	CcSEcCtD
Methsuximide—CYP2C19—Phase 1 - Functionalization of compounds—ALDH1A1—kidney cancer	0.0015	0.00598	CbGpPWpGaD
Methsuximide—Insomnia—Paclitaxel—kidney cancer	0.00149	0.00202	CcSEcCtD
Methsuximide—Leukopenia—Capecitabine—kidney cancer	0.00149	0.00201	CcSEcCtD
Methsuximide—Vomiting—Dactinomycin—kidney cancer	0.00148	0.002	CcSEcCtD
Methsuximide—Somnolence—Paclitaxel—kidney cancer	0.00147	0.00199	CcSEcCtD
Methsuximide—Rash—Dactinomycin—kidney cancer	0.00147	0.00198	CcSEcCtD
Methsuximide—Nausea—Sunitinib—kidney cancer	0.00146	0.00198	CcSEcCtD
Methsuximide—Pancytopenia—Doxorubicin—kidney cancer	0.00146	0.00197	CcSEcCtD
Methsuximide—CYP2C19—Biological oxidations—ACY1—kidney cancer	0.00146	0.00579	CbGpPWpGaD
Methsuximide—Decreased appetite—Paclitaxel—kidney cancer	0.00144	0.00194	CcSEcCtD
Methsuximide—Gastrointestinal disorder—Paclitaxel—kidney cancer	0.00143	0.00193	CcSEcCtD
Methsuximide—Diarrhoea—Vincristine—kidney cancer	0.00142	0.00192	CcSEcCtD
Methsuximide—Constipation—Paclitaxel—kidney cancer	0.00141	0.00191	CcSEcCtD
Methsuximide—CACNA1G—Regulation of nuclear beta catenin signaling and target gene transcription—CCND1—kidney cancer	0.0014	0.00557	CbGpPWpGaD
Methsuximide—CACNA1G—Regulation of nuclear beta catenin signaling and target gene transcription—JUN—kidney cancer	0.0014	0.00555	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—HNF1B—kidney cancer	0.00139	0.00555	CbGpPWpGaD
Methsuximide—Weight decreased—Doxorubicin—kidney cancer	0.00139	0.00188	CcSEcCtD
Methsuximide—CACNA1H—Corticotropin-releasing hormone—RAF1—kidney cancer	0.00139	0.00551	CbGpPWpGaD
Methsuximide—CACNA1G—Regulation of nuclear beta catenin signaling and target gene transcription—CTNNB1—kidney cancer	0.00138	0.00551	CbGpPWpGaD
Methsuximide—Nausea—Dactinomycin—kidney cancer	0.00138	0.00187	CcSEcCtD
Methsuximide—CACNA1H—Corticotropin-releasing hormone—RELA—kidney cancer	0.00138	0.00549	CbGpPWpGaD
Methsuximide—Dizziness—Vincristine—kidney cancer	0.00137	0.00186	CcSEcCtD
Methsuximide—Drowsiness—Doxorubicin—kidney cancer	0.00137	0.00185	CcSEcCtD
Methsuximide—Confusional state—Capecitabine—kidney cancer	0.00137	0.00185	CcSEcCtD
Methsuximide—Feeling abnormal—Paclitaxel—kidney cancer	0.00136	0.00184	CcSEcCtD
Methsuximide—Stevens-Johnson syndrome—Doxorubicin—kidney cancer	0.00136	0.00184	CcSEcCtD
Methsuximide—Phenobarbital—CYP1A1—kidney cancer	0.00135	0.141	CrCbGaD
Methsuximide—CACNA1I—Developmental Biology—CTNNA1—kidney cancer	0.00135	0.00539	CbGpPWpGaD
Methsuximide—Gastrointestinal pain—Paclitaxel—kidney cancer	0.00135	0.00183	CcSEcCtD
Methsuximide—Diarrhoea—Gemcitabine—kidney cancer	0.00135	0.00183	CcSEcCtD
Methsuximide—CACNA1H—Developmental Biology—HNF1B—kidney cancer	0.00135	0.00537	CbGpPWpGaD
Methsuximide—Vomiting—Vincristine—kidney cancer	0.00132	0.00179	CcSEcCtD
Methsuximide—CACNA1G—NCAM signaling for neurite out-growth—MAPK3—kidney cancer	0.00131	0.00523	CbGpPWpGaD
Methsuximide—Urticaria—Paclitaxel—kidney cancer	0.00131	0.00177	CcSEcCtD
Methsuximide—Rash—Vincristine—kidney cancer	0.00131	0.00177	CcSEcCtD
Methsuximide—Dermatitis—Vincristine—kidney cancer	0.00131	0.00177	CcSEcCtD
Methsuximide—Haematuria—Doxorubicin—kidney cancer	0.00131	0.00177	CcSEcCtD
Methsuximide—Abdominal pain—Paclitaxel—kidney cancer	0.00131	0.00177	CcSEcCtD
Methsuximide—Headache—Vincristine—kidney cancer	0.0013	0.00176	CcSEcCtD
Methsuximide—CACNA1I—Developmental Biology—PAX6—kidney cancer	0.0013	0.00516	CbGpPWpGaD
Methsuximide—Anorexia—Capecitabine—kidney cancer	0.00129	0.00175	CcSEcCtD
Methsuximide—CACNA1H—NCAM signaling for neurite out-growth—MAPK3—kidney cancer	0.00127	0.00506	CbGpPWpGaD
Methsuximide—Vomiting—Gemcitabine—kidney cancer	0.00125	0.0017	CcSEcCtD
Methsuximide—CACNA1G—NCAM signaling for neurite out-growth—MAPK1—kidney cancer	0.00125	0.00497	CbGpPWpGaD
Methsuximide—Rash—Gemcitabine—kidney cancer	0.00124	0.00168	CcSEcCtD
Methsuximide—Dermatitis—Gemcitabine—kidney cancer	0.00124	0.00168	CcSEcCtD
Methsuximide—CACNA1H—Corticotropin-releasing hormone—IL2—kidney cancer	0.00124	0.00494	CbGpPWpGaD
Methsuximide—Headache—Gemcitabine—kidney cancer	0.00124	0.00167	CcSEcCtD
Methsuximide—Nausea—Vincristine—kidney cancer	0.00123	0.00167	CcSEcCtD
Methsuximide—Insomnia—Capecitabine—kidney cancer	0.00123	0.00166	CcSEcCtD
Methsuximide—CACNA1H—NCAM signaling for neurite out-growth—MAPK1—kidney cancer	0.00121	0.00482	CbGpPWpGaD
Methsuximide—CACNA1H—Corticotropin-releasing hormone—CTNNB1—kidney cancer	0.0012	0.00477	CbGpPWpGaD
Methsuximide—CYP2C19—Constitutive Androstane Receptor Pathway—ABCB1—kidney cancer	0.00118	0.0047	CbGpPWpGaD
Methsuximide—CACNA1G—NCAM signaling for neurite out-growth—KRAS—kidney cancer	0.00118	0.0047	CbGpPWpGaD
Methsuximide—CYP2C19—Arachidonic acid metabolism—PTGS1—kidney cancer	0.00118	0.0047	CbGpPWpGaD
Methsuximide—Decreased appetite—Capecitabine—kidney cancer	0.00118	0.00159	CcSEcCtD
Methsuximide—CYP2C19—Melatonin metabolism and effects—CYP1A1—kidney cancer	0.00118	0.00468	CbGpPWpGaD
Methsuximide—Nausea—Gemcitabine—kidney cancer	0.00117	0.00158	CcSEcCtD
Methsuximide—Gastrointestinal disorder—Capecitabine—kidney cancer	0.00117	0.00158	CcSEcCtD
Methsuximide—Ketazolam—ABCB1—kidney cancer	0.00117	0.122	CrCbGaD
Methsuximide—Erythema multiforme—Doxorubicin—kidney cancer	0.00116	0.00157	CcSEcCtD
Methsuximide—CACNA1G—Axon guidance—PAK1—kidney cancer	0.00116	0.00462	CbGpPWpGaD
Methsuximide—Constipation—Capecitabine—kidney cancer	0.00116	0.00157	CcSEcCtD
Methsuximide—CACNA1H—NCAM signaling for neurite out-growth—KRAS—kidney cancer	0.00114	0.00455	CbGpPWpGaD
Methsuximide—Diarrhoea—Paclitaxel—kidney cancer	0.00113	0.00153	CcSEcCtD
Methsuximide—CACNA1H—Axon guidance—PAK1—kidney cancer	0.00112	0.00448	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—PAK1—kidney cancer	0.00112	0.00447	CbGpPWpGaD
Methsuximide—CACNA1G—Regulation of nuclear beta catenin signaling and target gene transcription—MYC—kidney cancer	0.00112	0.00446	CbGpPWpGaD
Methsuximide—Feeling abnormal—Capecitabine—kidney cancer	0.00112	0.00151	CcSEcCtD
Methsuximide—Gastrointestinal pain—Capecitabine—kidney cancer	0.00111	0.0015	CcSEcCtD
Methsuximide—Dizziness—Paclitaxel—kidney cancer	0.00109	0.00148	CcSEcCtD
Methsuximide—Urticaria—Capecitabine—kidney cancer	0.00108	0.00146	CcSEcCtD
Methsuximide—Abdominal pain—Capecitabine—kidney cancer	0.00107	0.00145	CcSEcCtD
Methsuximide—Tension—Doxorubicin—kidney cancer	0.00105	0.00142	CcSEcCtD
Methsuximide—Vomiting—Paclitaxel—kidney cancer	0.00105	0.00142	CcSEcCtD
Methsuximide—Rash—Paclitaxel—kidney cancer	0.00104	0.00141	CcSEcCtD
Methsuximide—Dermatitis—Paclitaxel—kidney cancer	0.00104	0.00141	CcSEcCtD
Methsuximide—Nervousness—Doxorubicin—kidney cancer	0.00104	0.00141	CcSEcCtD
Methsuximide—Headache—Paclitaxel—kidney cancer	0.00103	0.0014	CcSEcCtD
Methsuximide—Vision blurred—Doxorubicin—kidney cancer	0.00101	0.00136	CcSEcCtD
Methsuximide—CACNA1H—Corticotropin-releasing hormone—MAPK3—kidney cancer	0.000999	0.00397	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—CTNNA1—kidney cancer	0.000999	0.00397	CbGpPWpGaD
Methsuximide—Nausea—Paclitaxel—kidney cancer	0.000981	0.00133	CcSEcCtD
Methsuximide—CACNA1I—Axon guidance—KDR—kidney cancer	0.00098	0.0039	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—CTNNA1—kidney cancer	0.000967	0.00385	CbGpPWpGaD
Methsuximide—CACNA1I—Axon guidance—MET—kidney cancer	0.000959	0.00382	CbGpPWpGaD
Methsuximide—Leukopenia—Doxorubicin—kidney cancer	0.000958	0.0013	CcSEcCtD
Methsuximide—CACNA1G—Developmental Biology—PAX6—kidney cancer	0.000956	0.0038	CbGpPWpGaD
Methsuximide—CACNA1H—Corticotropin-releasing hormone—MAPK1—kidney cancer	0.00095	0.00378	CbGpPWpGaD
Methsuximide—Diarrhoea—Capecitabine—kidney cancer	0.000927	0.00125	CcSEcCtD
Methsuximide—CACNA1H—Developmental Biology—PAX6—kidney cancer	0.000926	0.00368	CbGpPWpGaD
Methsuximide—Dizziness—Capecitabine—kidney cancer	0.000896	0.00121	CcSEcCtD
Methsuximide—Confusional state—Doxorubicin—kidney cancer	0.000881	0.00119	CcSEcCtD
Methsuximide—Vomiting—Capecitabine—kidney cancer	0.000862	0.00117	CcSEcCtD
Methsuximide—Rash—Capecitabine—kidney cancer	0.000854	0.00116	CcSEcCtD
Methsuximide—Dermatitis—Capecitabine—kidney cancer	0.000854	0.00115	CcSEcCtD
Methsuximide—Headache—Capecitabine—kidney cancer	0.000849	0.00115	CcSEcCtD
Methsuximide—Anorexia—Doxorubicin—kidney cancer	0.000833	0.00113	CcSEcCtD
Methsuximide—CACNA1G—Developmental Biology—PAK1—kidney cancer	0.000829	0.0033	CbGpPWpGaD
Methsuximide—CYP2C19—Phase 1 - Functionalization of compounds—PTGS1—kidney cancer	0.000827	0.00329	CbGpPWpGaD
Methsuximide—Clobazam—ABCB1—kidney cancer	0.000824	0.0859	CrCbGaD
Methsuximide—Nausea—Capecitabine—kidney cancer	0.000805	0.00109	CcSEcCtD
Methsuximide—CACNA1H—Developmental Biology—PAK1—kidney cancer	0.000802	0.00319	CbGpPWpGaD
Methsuximide—CYP2C19—Biological oxidations—ALDH1A1—kidney cancer	0.000797	0.00317	CbGpPWpGaD
Methsuximide—Insomnia—Doxorubicin—kidney cancer	0.00079	0.00107	CcSEcCtD
Methsuximide—Somnolence—Doxorubicin—kidney cancer	0.000777	0.00105	CcSEcCtD
Methsuximide—CYP2C19—Arachidonic acid metabolism—CYP1A1—kidney cancer	0.00076	0.00303	CbGpPWpGaD
Methsuximide—Decreased appetite—Doxorubicin—kidney cancer	0.000759	0.00103	CcSEcCtD
Methsuximide—Gastrointestinal disorder—Doxorubicin—kidney cancer	0.000754	0.00102	CcSEcCtD
Methsuximide—Phenytoin—ABCB1—kidney cancer	0.000751	0.0784	CrCbGaD
Methsuximide—Constipation—Doxorubicin—kidney cancer	0.000747	0.00101	CcSEcCtD
Methsuximide—CACNA1G—Axon guidance—KDR—kidney cancer	0.000723	0.00288	CbGpPWpGaD
Methsuximide—Phenobarbital—ABCB1—kidney cancer	0.00072	0.0751	CrCbGaD
Methsuximide—Feeling abnormal—Doxorubicin—kidney cancer	0.00072	0.000974	CcSEcCtD
Methsuximide—Gastrointestinal pain—Doxorubicin—kidney cancer	0.000714	0.000966	CcSEcCtD
Methsuximide—CACNA1I—Axon guidance—RAF1—kidney cancer	0.000709	0.00282	CbGpPWpGaD
Methsuximide—CACNA1G—Axon guidance—MET—kidney cancer	0.000707	0.00281	CbGpPWpGaD
Methsuximide—CACNA1I—Axon guidance—ERBB2—kidney cancer	0.000701	0.00279	CbGpPWpGaD
Methsuximide—CACNA1H—Axon guidance—KDR—kidney cancer	0.0007	0.00279	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—KDR—kidney cancer	0.000699	0.00278	CbGpPWpGaD
Methsuximide—Urticaria—Doxorubicin—kidney cancer	0.000694	0.000939	CcSEcCtD
Methsuximide—Abdominal pain—Doxorubicin—kidney cancer	0.000691	0.000934	CcSEcCtD
Methsuximide—CACNA1H—Axon guidance—MET—kidney cancer	0.000685	0.00273	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—MET—kidney cancer	0.000685	0.00272	CbGpPWpGaD
Methsuximide—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP1A1—kidney cancer	0.000657	0.00262	CbGpPWpGaD
Methsuximide—CYP2C19—Oxidation by Cytochrome P450—CYP1A1—kidney cancer	0.000649	0.00258	CbGpPWpGaD
Methsuximide—Diarrhoea—Doxorubicin—kidney cancer	0.000598	0.000809	CcSEcCtD
Methsuximide—Dizziness—Doxorubicin—kidney cancer	0.000578	0.000781	CcSEcCtD
Methsuximide—Vomiting—Doxorubicin—kidney cancer	0.000555	0.000751	CcSEcCtD
Methsuximide—Rash—Doxorubicin—kidney cancer	0.000551	0.000745	CcSEcCtD
Methsuximide—Dermatitis—Doxorubicin—kidney cancer	0.00055	0.000744	CcSEcCtD
Methsuximide—Headache—Doxorubicin—kidney cancer	0.000547	0.00074	CcSEcCtD
Methsuximide—CACNA1I—Axon guidance—VEGFA—kidney cancer	0.00054	0.00215	CbGpPWpGaD
Methsuximide—CYP2C19—Phase 1 - Functionalization of compounds—CYP1A1—kidney cancer	0.000533	0.00212	CbGpPWpGaD
Methsuximide—CACNA1G—Axon guidance—RAF1—kidney cancer	0.000522	0.00208	CbGpPWpGaD
Methsuximide—Nausea—Doxorubicin—kidney cancer	0.000519	0.000702	CcSEcCtD
Methsuximide—CACNA1G—Axon guidance—ERBB2—kidney cancer	0.000517	0.00206	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—KDR—kidney cancer	0.000516	0.00205	CbGpPWpGaD
Methsuximide—CACNA1I—Axon guidance—MAPK3—kidney cancer	0.000511	0.00203	CbGpPWpGaD
Methsuximide—CACNA1H—Axon guidance—RAF1—kidney cancer	0.000506	0.00201	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—RAF1—kidney cancer	0.000506	0.00201	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—MET—kidney cancer	0.000505	0.00201	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—RELA—kidney cancer	0.000503	0.002	CbGpPWpGaD
Methsuximide—CACNA1H—Axon guidance—ERBB2—kidney cancer	0.000501	0.00199	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—ERBB2—kidney cancer	0.0005	0.00199	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—KDR—kidney cancer	0.000499	0.00199	CbGpPWpGaD
Methsuximide—CYP2C19—Cytochrome P450 - arranged by substrate type—POMC—kidney cancer	0.00049	0.00195	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—MET—kidney cancer	0.000489	0.00195	CbGpPWpGaD
Methsuximide—CACNA1I—Axon guidance—MAPK1—kidney cancer	0.000486	0.00193	CbGpPWpGaD
Methsuximide—CYP2C19—Biological oxidations—GSTT1—kidney cancer	0.000469	0.00187	CbGpPWpGaD
Methsuximide—CACNA1I—Axon guidance—KRAS—kidney cancer	0.000459	0.00183	CbGpPWpGaD
Methsuximide—CYP2C19—Arachidonic acid metabolism—PTGS2—kidney cancer	0.000452	0.0018	CbGpPWpGaD
Methsuximide—CYP2C19—Biological oxidations—PTGS1—kidney cancer	0.000439	0.00175	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—CTNNB1—kidney cancer	0.000438	0.00174	CbGpPWpGaD
Methsuximide—CACNA1G—Axon guidance—VEGFA—kidney cancer	0.000398	0.00158	CbGpPWpGaD
Methsuximide—CYP2C19—Phase 1 - Functionalization of compounds—POMC—kidney cancer	0.000397	0.00158	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism of lipids and lipoproteins—GLIPR1—kidney cancer	0.000387	0.00154	CbGpPWpGaD
Methsuximide—CACNA1H—Axon guidance—VEGFA—kidney cancer	0.000386	0.00153	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—VEGFA—kidney cancer	0.000385	0.00153	CbGpPWpGaD
Methsuximide—CACNA1G—Axon guidance—MAPK3—kidney cancer	0.000377	0.0015	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—RAF1—kidney cancer	0.000373	0.00148	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—RELA—kidney cancer	0.000371	0.00148	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—ERBB2—kidney cancer	0.000369	0.00147	CbGpPWpGaD
Methsuximide—CACNA1H—Axon guidance—MAPK3—kidney cancer	0.000365	0.00145	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—MAPK3—kidney cancer	0.000365	0.00145	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—RAF1—kidney cancer	0.000361	0.00144	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—RELA—kidney cancer	0.000359	0.00143	CbGpPWpGaD
Methsuximide—CACNA1G—Axon guidance—MAPK1—kidney cancer	0.000358	0.00143	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—ERBB2—kidney cancer	0.000357	0.00142	CbGpPWpGaD
Methsuximide—CACNA1H—Axon guidance—MAPK1—kidney cancer	0.000347	0.00138	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—MAPK1—kidney cancer	0.000347	0.00138	CbGpPWpGaD
Methsuximide—CACNA1G—Axon guidance—KRAS—kidney cancer	0.000338	0.00135	CbGpPWpGaD
Methsuximide—CACNA1H—Axon guidance—KRAS—kidney cancer	0.000328	0.0013	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—KRAS—kidney cancer	0.000328	0.0013	CbGpPWpGaD
Methsuximide—CYP2C19—Biological oxidations—GSTP1—kidney cancer	0.000325	0.00129	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—CTNNB1—kidney cancer	0.000323	0.00128	CbGpPWpGaD
Methsuximide—CYP2C19—Metapathway biotransformation—GSTP1—kidney cancer	0.00032	0.00128	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—CTNNB1—kidney cancer	0.000313	0.00124	CbGpPWpGaD
Methsuximide—CYP2C19—Biological oxidations—GSTM1—kidney cancer	0.000299	0.00119	CbGpPWpGaD
Methsuximide—CYP2C19—Metapathway biotransformation—GSTM1—kidney cancer	0.000294	0.00117	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—VEGFA—kidney cancer	0.000284	0.00113	CbGpPWpGaD
Methsuximide—CYP2C19—Biological oxidations—CYP1A1—kidney cancer	0.000283	0.00113	CbGpPWpGaD
Methsuximide—CYP2C19—Metapathway biotransformation—CYP1A1—kidney cancer	0.000279	0.00111	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—VEGFA—kidney cancer	0.000275	0.0011	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—MAPK3—kidney cancer	0.000269	0.00107	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—MAPK3—kidney cancer	0.00026	0.00104	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—MAPK1—kidney cancer	0.000256	0.00102	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—ACY1—kidney cancer	0.000249	0.000991	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—MAPK1—kidney cancer	0.000248	0.000986	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—KRAS—kidney cancer	0.000242	0.000961	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—KRAS—kidney cancer	0.000234	0.000931	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism of lipids and lipoproteins—CRABP1—kidney cancer	0.000212	0.000845	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—PDHB—kidney cancer	0.000212	0.000842	CbGpPWpGaD
Methsuximide—CYP2C19—Biological oxidations—POMC—kidney cancer	0.000211	0.00084	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—CCBL1—kidney cancer	0.000199	0.000792	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism of lipids and lipoproteins—ACHE—kidney cancer	0.00018	0.000716	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—PPAT—kidney cancer	0.000173	0.000687	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—GLIPR1—kidney cancer	0.000173	0.000687	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism of lipids and lipoproteins—SCARB1—kidney cancer	0.00017	0.000678	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism of lipids and lipoproteins—PTGS1—kidney cancer	0.000169	0.000671	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—FH—kidney cancer	0.00016	0.000638	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—APRT—kidney cancer	0.00016	0.000638	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism of lipids and lipoproteins—BCHE—kidney cancer	0.000157	0.000624	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—GPC3—kidney cancer	0.000151	0.0006	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—CA2—kidney cancer	0.000147	0.000584	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—ALAD—kidney cancer	0.000143	0.000569	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—ST3GAL2—kidney cancer	0.00014	0.000555	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—ALDH1A1—kidney cancer	0.000136	0.000543	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—PGK1—kidney cancer	0.000131	0.00052	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—SLC5A3—kidney cancer	0.000131	0.00052	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—LDHB—kidney cancer	0.000128	0.00051	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—CA9—kidney cancer	0.000111	0.000443	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism of lipids and lipoproteins—CYP1A1—kidney cancer	0.000109	0.000433	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—CRABP1—kidney cancer	9.45e-05	0.000376	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—ITPR2—kidney cancer	8.79e-05	0.00035	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism of lipids and lipoproteins—POMC—kidney cancer	8.1e-05	0.000322	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—ACHE—kidney cancer	8.01e-05	0.000319	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—GSTT1—kidney cancer	8.01e-05	0.000319	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—SCARB1—kidney cancer	7.59e-05	0.000302	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—PTGS1—kidney cancer	7.51e-05	0.000299	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—PSMD7—kidney cancer	7.36e-05	0.000293	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—BCHE—kidney cancer	6.98e-05	0.000278	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—SLC5A5—kidney cancer	6.9e-05	0.000275	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—SLC2A1—kidney cancer	6.66e-05	0.000265	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	6.46e-05	0.000257	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	5.64e-05	0.000224	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—GSTP1—kidney cancer	5.56e-05	0.000221	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—ABCB1—kidney cancer	5.26e-05	0.000209	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—GSTM1—kidney cancer	5.1e-05	0.000203	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—CYP1A1—kidney cancer	4.84e-05	0.000193	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	3.98e-05	0.000158	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—POMC—kidney cancer	3.61e-05	0.000144	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—PTGS2—kidney cancer	2.88e-05	0.000115	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—PTEN—kidney cancer	2.51e-05	9.99e-05	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—PIK3CA—kidney cancer	1.77e-05	7.05e-05	CbGpPWpGaD
